[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 9, 2000

Immunologic Strategies for Herpes Vaccination

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(6):746. doi:10.1001/jama.283.6.741

To the Editor: Dr Corey and colleagues1 reported that a recombinant glycoprotein vaccine failed to prevent genital herpes simplex virus 2 (HSV-2) infection. The study evaluated asymptomatic and symptomatic infections and symptomatic recurrences. None of these outcomes were modified by vaccine despite neutralizing and antibody titers that exceeded those produced during naturally acquired HSV-2 infection. The authors suggest that more information is needed about cellular and mucosal immune responses to HSV-2 infection before "we can attempt to identify laboratory-based correlates of immune protection." While more information would be helpful, the authors failed to consider currently available information that is relevant to the vaccine failure.

First Page Preview View Large
First page PDF preview
First page PDF preview
×